CHF Solutions Submits Patent Application for New and Improved Diagnostic Parameters to Support Hemodynamic Stability
Aquadex SmartFlow currently provides critical patient information to assist clinicians in the precise delivery of ultrafiltration therapy. The new innovations included in this patent application will improve key diagnostic information to support hemodynamic stability in patients. The non-invasive technology provides accurate and more timely cardiovascular parameters for metrics such as systemic vascular resistance and hematocrit in an intuitive presentation.
“At CHF Solutions, we continue to invest in technological advancements that have a meaningful impact for patients and clinicians,” said Nestor Jaramillo, Jr., President and CEO of CHF Solutions. “Clinicians rely on us to provide intuitive technology that helps them make the smartest decisions for their patients, which is why we continuously work on improvements that expand capabilities and foster confidence in our ultrafiltration therapy. This patent application is the first step to offering new and improved metrics that indicate a change in the fluid management approach may be warranted.”
Fluid overload is a major issue among critically ill children and adults and contributes to increased length of hospitalizations and readmissions.1 Ultrafiltration with Aquadex™ is associated with a higher cumulative fluid loss, higher net fluid loss and greater relative reduction in body weight when compared to pharmacologic therapy.2
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the benefits of innovations contained in the patent application. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
1 Costanzo MR et al. JACC. 2017;69(19):2428-45.
2 Grodin, J et al.
Claudia Napal DraytonChief Financial Officer, CHF Solutions, Inc.952-345-4205 email@example.com Matt Bacso, CFA Gilmartin Group LLCMatt.firstname.lastname@example.org MEDIA: Jessica StebingHealth+Commerce 260-336-6202 email@example.com
Source: CHF Solutions, Inc.